Literature DB >> 18573158

Metastatic Crohn's disease: a review.

I Palamaras1, J El-Jabbour, N Pietropaolo, P Thomson, S Mann, W Robles, H P Stevens.   

Abstract

Metastatic Crohn's disease (MCD) indicates the presence of non-caseating granuloma of the skin at sites separated from the gastrointestinal tract by normal tissue and is the least common dermatologic manifestation of CD. In adults, MCD usually appears after the initial diagnosis of CD in 70% of cases, whereas in children, it appears at the same time as CD in almost half of the cases. The most frequent skin lesions in adults are nodules, plaques with or without ulceration on the extremities and ulcers on the genitals. In children, genital swelling with or without erythema is the most frequent presentation of MCD. Simultaneous presence of perianal CD affects more females (60%) and particularly children. Associated gastrointestinal symptoms are present in one third of the cases in adults and in half of the cases in children. Treatment is often unsatisfactory. Randomised controlled trials are lacking. Various chemotherapeutic agents have been used such as oral metronidazole, topical and/or oral steroids, azathioprine, cyclosporine, sulfasalazine, tetracyclines, topical or systemic tacrolimus, infliximab alone or with methotrexate, and surgical treatment with oral zinc sulphate. MCD represents another 'great imitator'. This reviews the most relevant characteristics of this disease, in order to increase awareness and to avoid delay in diagnosis and improve management of the whole CD complex.

Entities:  

Mesh:

Year:  2008        PMID: 18573158     DOI: 10.1111/j.1468-3083.2008.02741.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  15 in total

1.  Case: Metastatic Crohn's disease of the genitalia in a prepubescent male: An illustrative case of an uncommon diagnosis.

Authors:  Sandra S Y Kim; Ryan K Flannigan; Dinesh Samarasekera; Jefferson Terry; Andrew E Macneily
Journal:  Can Urol Assoc J       Date:  2017-09       Impact factor: 1.862

Review 2.  Skin Manifestations of Inflammatory Bowel Disease.

Authors:  Thomas Greuter; Alexander Navarini; Stephan R Vavricka
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

3.  Metastatic Crohn Disease with Groin Localization in an Adult Patient.

Authors:  Duygu Gulseren; Sibel Ersoy-Evans
Journal:  Dermatol Pract Concept       Date:  2022-04-01

4.  [Cheilitis granulomatosa as initial manifestation of Crohn's disease].

Authors:  G Rehor; M Braun-Falco; D Nashan; F Meiss
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

Review 5.  Current clinical issue of skin lesions in patients with inflammatory bowel disease.

Authors:  Tomoya Iida; Tokimasa Hida; Minoru Matsuura; Hisashi Uhara; Hiroshi Nakase
Journal:  Clin J Gastroenterol       Date:  2019-03-05

Review 6.  Management of cutaneous disorders related to inflammatory bowel disease.

Authors:  Zaira Pellicer; Jesus Manuel Santiago; Alejandro Rodriguez; Vicent Alonso; Rosario Antón; Marta Maia Bosca
Journal:  Ann Gastroenterol       Date:  2012

Review 7.  Crohn's disease in women.

Authors:  Ivana Plavšić; Tea Stimac; Goran Hauser
Journal:  Int J Womens Health       Date:  2013-10-18

8.  Severe contiguous perianal Crohn's disease.

Authors:  Tricie K Toledo; Helena R Camasmie; Carlos A F Athayde; Ricardo B Lima; Antonio M D'Acri; Carlos J Martins; Omar Lupi
Journal:  JAAD Case Rep       Date:  2016-03-21

9.  Topical tacrolimus 0.1% ointment for treatment of cutaneous Crohn's Disease.

Authors:  Shantini A Rice; Pick N Woo; Emad El-Omar; Ronald A Keenan; Anthony D Ormerod
Journal:  BMC Res Notes       Date:  2013-01-18

10.  Paradoxical Autoinflammatory Skin Reaction to Tumor Necrosis Factor Alpha Blockers Manifesting as Amicrobial Pustulosis of the Folds in Patients With Inflammatory Bowel Diseases.

Authors:  Angelo V Marzano; Simona Tavecchio; Emilio Berti; Carlo Gelmetti; Massimo Cugno
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.